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Previous occurrence of life-threatening
abdominal infection is not a contraindication
to bone marrow transplantation
Sir,
Protracted severe infections during the post-induc-
tion aplastic phase in leukemic patients may cause
delay and/or modification of the planned treatment
strategy;1 in particular, patients may be considered
no longer eligible for bone marrow transplantation
(BMT) owing to a high risk of suffering infection reac-
tivation.2,3
We report on seven patients admitted to our Unit
because of acute myeloid leukemia, who received
additional intensive chemotherapy followed by allo-
geneic or autologous BMT, in spite of a recent
episode of life-threatening clinically documented
abdominal infection (CDAI) (Table 1). These infec-
tions appeared during the aplastic phase after induc-
tion treatment given according to the EORTC-
GIMEMA AML 10 Protocol. All patients had high
fever, severe abdominal symptoms (diffuse pain and
tenderness, vomiting, diarrhea and/or melena); they
had abnormal ultrasound (US) findings, character-
ized by terminal ileal loop overdistension and wall
thickening (> 6 mm in patients #1 and 2; 5 mm in
patient #3), by an intrasplenic spherical hypoechoic
lesion (3.5 cm) in patient #4 and by dilated fluid-
filled ileal loops in patients #5, 6 and 7. All patients
received conservative medical management with
bowel rest (naso-gastric suction and total parenter-
al nutrition), antimicrobial coverage (including anti-
anaerobic and antimycotic drugs) and G-CSF. They
all recovered from the infection and received the sub-
sequent consolidation treatment (containing either
idarubicin or mitoxantrone or daunorubicin in com-
bination with cytarabine) with a minor delay. Then,
according to the protocol, all patients were trans-
planted, using the same BU-Cy conditioning regimen
and a standard antimicrobial prophylaxis (ciproflo-
xacin, fluconazole and acyclovir). None had pre-emp-
tive parenteral nutrition or glutamine supplementa-
tion or growth factors; the allografted patients
received CsA plus a short course of MTX as acute
GvHD prophylaxis. The median interval from diag-
nosis of CDAI to BMT was 3.5 months (range 2-6).
All patients achieved complete hematologic
engraftment with a median duration of severe neu-
tropenia of 13 days (range 12-15). No transplant-
related mortality was observed; no early or late
abdominal complications occurred in any patient. In
the post-transplant period, three patients developed
an episode of fever of unknown origin, which rapid-
ly responded to broad-spectrum antibiotic treat-
ment. In patient #4, in whom the clinical resolution
of a splenic abscess was associated with a persistently
abnormal US spleen scan, the residual hypoechoic
lesion continued to improve after BMT. Patients #2
and 4 died from leukemia relapse six and four months
post-BMT, respectively; the others are alive and
healthy, in complete hematologic remission at 8, 4,
32, 45 and 36 months post-BMT.
Severe abdominal infections may occur in about
one third of acute leukemia patients undergoing
intensive chemotherapy according to the EORTC-
GIMEMA-AML 10 Protocol;4,5 probably dosage and
modality of cytarabine administration are relevant
for the development of such complications.4,6 Our
small series shows that patients who have recovered
from a life-threatening abdominal infection can safe-
ly receive additional chemotherapy courses followed
by allogeneic or autologous BMT, without major
delay or modification of the planned treatment strat-
egy; there is no need for secondary broad-spectrum
antimicrobial prophylaxis or pre-emptive nutritional
support8 or growth factors.2 We confirm that these
complications appear more often after induction
than after consolidation4,5 and that they can be suc-
cessfully treated with vigorous conservative medical
management,5,7 if an early diagnosis is made.5 It may
be relevant that all patients in our series were condi-
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Table 1. Characteristics of patients who received BMT in spite of a prior life-threatening abdominal infection.
Pt. Sex, age Type of Interval from infection Type of BMT-related Outcome
(years) infection to BMT (months) BMT complications
1 M, 61 ileocecitis 6 autologous none alive
2 F, 26 ileocecitis 3 allogeneic none died from leukemia relapse 
3 F, 25 borderline ileocecitis 3 autologous none alive
4 M, 49 spleen abscess 2.5 allogeneic none died from leukemia relapse
5 F, 53 gut-syndrome 4 autologous 1 episode of FUO alive
6 F, 25 gut-syndrome 3 allogeneic 1 episode of FUO alive
7 M, 18 gut-syndrome 2 autologous 1 episode of FUO alive
FUO= fever of unknown origin, BMT= bone marrow transplantation, gut-syndrome= syndrome characterized by high fever, severe abdominal pain and tenderness,
vomiting, diarrhea and/or melena, without ultrasound finding of ileal wall thickening.
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tioned with Bu-Cy; we do not know whether more
gut-toxic conditioning regimens (e.g. TBI) are equal-
ly safe in this group of patients. 
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Splenic inflammatory pseudotumor mimicking
primary splenic malignancy
Sir,
We report the case of a patient with splenic inflam-
matory pseudotumor (IPT). Recognition of this rare
entity is important because the clinical manifesta-
tions and radiographic features may be indistin-
guishable from a malignant lymphoproliferative dis-
order. 
A 52-year old woman was admitted to hospital for
evaluation of a 6-week history of fever, chills and night
sweats. Physical examination was remarkable only for
palpable non-tender splenomegaly. The pertinent lab-
oratory tests were: ESR 100 mm/hour, microcytic
hypochromic anemia (hemoglobin 8.5-9.5 g/dL) and
persistent leukocytosis (25,500/mm3). Various sero-
logic tests were all negative. Abdominal CT demon-
strated splenomegaly with a non-homogenous focal
lesion in the upper pole (7.536.6 cm) with septa and
coarse calcifications. 67Gallium scan demonstrated a
pathologic uptake in this region. CT guided fine nee-
dle aspirate (FNA) yielded 3 mL of sterile fluid. Cyto-
logic examination of the aspirated fluid showed abun-
dant lymphocytes, histiocytes and granulocytes. The
patient was treated with intravenous antibiotics but
failed to respond to therapy and a splenectomy was
performed. On gross pathologic examination the
spleen weighed 430 g. Cross-section of the spleen
revealed a firm single yellow-gray, circumscribed mass
in the upper pole, containing focal areas of calcifica-
tions and an area of necrosis. Histologic examination
revealed spindle-shaped cells which were stained with
smooth muscle actin and vimentin surrounded by
large numbers of lymphocytes. After 3 years of follow-
up, the patient is asymptomatic, with a normal ESR
and leukocyte count.
IPT is a lesion of disputed etiology characterized
by proliferation of myofibroblasts accompanied by a
prominent inflammatory component. Although the
lung is the best known and most common site, IPT
occurs in diverse extra pulmonary locations including
the spleen.1,2 IPT of the spleen is extremely rare and
occurs in adults, with a propensity in middle-aged
individuals.3 Microscopically, the lesions are com-
posed of a variable mixture of inflammatory cells
within spindle cell proliferation. Coagulative necrosis
is located centrally in most patients, neutrophilic
leukocytes dominating in the presence of necrosis.
Our patient presented with a 6-week history of fever
and chills, night sweats, splenomegaly, high ESR,
anemia, and persistent leukocytosis. These are the
most frequent symptoms and signs observed in
patients with splenic abscess.4,5 CT guided FNA per-
formed in the patient yielded 3 mL of sterile fluid,
but the cytologic findings of abundant lymphocytes,
histiocytes and granulocytes were consistent with
abscess. The patient was immunocompetent with-
out evidence of a predisposing condition or bacteri-
al infection. Despite this fact, we erroneously diag-
nosed and treated the patient as having a splenic
abscess. Combined therapy with antibiotics and per-
cutaneous drainage of splenic abscesses have been
demonstrated to be an effective and safe proce-
dure.6,7 After 3 weeks a splenectomy was performed
and histopathologic examination showed IPT. The
